Sonnet BioTherapeutics CH SA
Development of a new cure for diabetic neuropathy
Sonnet BioTherapeutics CH SA is a biotech company that develops new treatment for neuropathy. In particular Sonnet is about to initiate clinical trial for a new cure for Chemotherapy Induced Peripheral Neuropathy and Diabetic Neuropathy. Sonnet BioTherapeutics CH SA belongs to the US group Sonnet BioTherapeutics holding Inc. whihc main focus is the use of cytokines attached to a fully human, proprietary Albumin Binding Domain for the treatment of oncologic indications.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
02.04.2024
A positive growth trajectory for three pharmaceutical startups (startupticker.ch)
29.07.2021
Relief Therapeutics announces CHF 15 million private placement (startupticker.ch)
22.03.2021
Relief places a bet on a second product (startupticker.ch)
21.09.2020
Relief inks partnership for commercialisation of Covid-19 treatment (startupticker.ch)
No milestones
No Jobs
No videos and documents
Venture Leaders Technology
The Venture Leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
Sonnet BioTherapeutics CH SA
Development of a new cure for diabetic neuropathy
Website:
sonnetbio.com/
Headquarter:
Yvonand
Foundation Date:
May 2013
Technology:
- Biotech
Sectors:
- Biotech
- Drug discovery
Support received
